Given a document and an entity the task is to select the author's sentiment towards the entity. Sentiments can be Positive, Neutral and Negative. Select Positive if the article expresses a positive view towards the given entity or praises its quality or skills. Select Neutral if the document expresses no clear view towards the entity or has equal amounts of positive and negative statements or expressing some fact/quote by someone else. Select Negative if the article expresses a negative view towards like harsh remarks, criticizing entities action/decision etc. Note that URLs in the text have been replaced with [Link].

Ex Input:
What is the sentiment of the following document towards the entity Ablynx ? PARIS/LONDON (Reuters) - French drugmaker Sanofi has agreed to buy  Belgian biotech company Ablynx  for 3.9 billion euros ($4.8 billion)  beating Novo Nordisk and marking its second big deal this month after buying Bioverativ.
The deal is a further sign of accelerating merger and acquisition (M&A) activity in the global biotech sector and comes after  Ablynx  rejected a 2.6 billion euro offer from Denmark’s Novo Nordisk.
Sanofi said on Monday it would pay 45 euros per share in cash for Ablynx  a premium of 21 percent over its closing price on Friday - and more than double the price before Novo went public with its initial bid.
Novo Nordisk conceded defeat  saying it did not intend to make a revised offer for Ablynx  which is developing a prized experimental drug for a rare blood disorder.
Sanofi said  Ablynx  would boost long-term value for  its  shareholders  while the takeover was expected to have a neutral impact on Sanofi’s business earnings per share (EPS) in 2018 and 2019.
Sanofi is already one of  Ablynx ’s big pharma partners  after striking a deal in July 2017 to find new treatments for inflammatory diseases.
By buying the company outright it will now get access to  Ablynx ’s most promising asset  the experimental drug caplacizumab for treating the rare bleeding disorder acquired thrombotic thrombocytopenic purpura.
Sanofi will be able to use its existing infrastructure and the recently acquired platform from Bioverativ to help to commercialize caplacizumab. It will also benefit from some of the other drugs  Ablynx  is working on  such as an infant anti-viral treatment  that would not have fitted within Novo Nordisk.
Berenberg analysts said  Ablynx  was a good fit but they estimated the deal would generate no more than a 4 percent return on invested capital  assuming caplacizumab sales of around 400 million euros by 2023.
The Danish group has sat out previous rounds of M&A in the drugs sector to focus on its core diabetes business but it now needs to find new products for its struggling smaller biopharmaceutical unit  where Ablynx would have been a good fit.
Morgan Stanley and Lazard advised Sanofi on the deal while JP Morgan advised Ablynx.

Ex Output:
Positive


Ex Input:
What is the sentiment of the following document towards the entity Hari Menon ? Investors picked up stakes in BigBasket through secondary share purchases as well   chief executive Hari Menon  told Reuters on Friday  declining to give a breakdown other than to say Alibaba now owns the biggest slice.
BigBasket  which sells everything from vegetables to shampoo  will use the funds to improve its technology  analytics  infrastructure and marketing   Menon  said.
The Bengaluru-headquartered firm  which also plans to build farmer networks and expand deeper into Indian cities where they operate  expects to break even between 2020 and 2022   Menon  added.
BigBasket is planning to sign a deal with Paytm E-Commerce that runs online marketplace  Paytm Mall  allowing both firms to leverage each others strengths   Menon  said.
Under the deal  which will become effective in the first half of this year  Paytm will become the default payments provider to BigBasket while BigBasket will be able to cross-sell groceries on Paytm Mall   Menon  said.

Ex Output:
Neutral


Ex Input:
What is the sentiment of the following document towards the entity Josh McDaniels ? Tuesday morning  Peter Schrager of FoxSports.com and NFL Networkâs Good Morning Football reported that  New England Patriots offensive coordinator Josh McDaniels  would break routine and skip this weekâs annual NFL Combine in Indianapolis  avoiding the city McDaniels jilted when  he  backed out on a verbal agreement to become the Coltsâ next head coach on Feb. 6  leaving many of  his  assistants in the lurch  too.
And the McDaniels news was a reminder that while itâs too early to judge Pat Shurmur as a head coach  the Giantsâ hiring of  him  certainly feels as if itâs put them in the strongest and most stable position they could have hoped for to operate at this Combine â and in free agency and in Aprilâs draft â especially considering the alternatives.
Imagine if the Giants had chosen  McDaniels  to be their next head coach and  McDaniels  had backed out on the Giants on Feb. 6  as he did the Colts. The Giants wouldnât have hired their next coach until two weeks ago at best  as the Colts did by pivoting to Eagles offensive coordinator Frank Reich. And the Giants in that scenario probably wouldnât have their full coaching staff together yet still  and theyâd be arriving at the Combine still in transition mode.
Perhaps most importantly  a negative perception of the Giantsâ operations may have lingered if  McDaniels  had reversed course on them. Fairly or unfairly  that would have had people connecting the turmoil of 2017 to an ominous and bad start to 2018  continuing to question the Giantsâ judgment for trying to hire someone who wasnât even ready.
Josh McDaniels. (Maddie Meyer/Getty Images)

Ex Output:

Positive